|
Gene Therapy
Citations 141-150 of 434 total displayed.
|
Past content
(since Aug 1998):
|
Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins
- Tie Chi Lei and David W. Scott
Blood 2005; 105: 4865-4870.
[Abstract]
[Full text]
[PDF]
Systemic protein delivery by muscle-gene transfer is limited by a local immune response
- Lixin Wang, Eric Dobrzynski, Alexander Schlachterman, Ou Cao, and Roland W. Herzog
Blood 2005; 105: 4226-4234.
[Abstract]
[Full text]
[PDF]
Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis
- Ute Modlich, Olga S. Kustikova, Manfred Schmidt, Cornelia Rudolph, Johann Meyer, Zhixiong Li, Kenji Kamino, Nils von Neuhoff, Brigitte Schlegelberger, Klaus Kuehlcke, Kevin D. Bunting, Sonja Schmidt, Annette Deichmann, Christof von Kalle, Boris Fehse, and Christopher Baum
Blood 2005; 105: 4235-4246.
[Abstract]
[Full text]
[PDF]
An inducible caspase 9 safety switch for T-cell therapy
- Karin C. Straathof, Martin A. Pulè, Patricia Yotnda, Gianpietro Dotti, Elio F. Vanin, Malcolm K. Brenner, Helen E. Heslop, David M. Spencer, and Cliona M. Rooney
Blood 2005; 105: 4247-4254.
[Abstract]
[Full text]
[PDF]
Failure of SCID-X1 gene therapy in older patients
- Adrian J. Thrasher, Salima Hacein-Bey-Abina, H. Bobby Gaspar, Stephane Blanche, E. Graham Davies, Kathryn Parsley, Kimberly Gilmour, Douglas King, Steven Howe, Joanna Sinclair, Christophe Hue, Frédérique Carlier, Christof von Kalle, Geneviève de Saint Basile, Françoise le Deist, Alain Fischer, and Marina Cavazzana-Calvo
Blood 2005; 105: 4255-4257.
[Abstract]
[Full text]
[PDF]
Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy
- Peng H. Tan, Sven C. Beutelspacher, Shao-An Xue, Yao-He Wang, Peter Mitchell, James C. McAlister, D. Frank P. Larkin, Myra O. McClure, Hans J. Stauss, Mary A. Ritter, Giovanna Lombardi, and Andrew J. T. George
Blood 2005; 105: 3824-3832.
[Abstract]
[Full text]
[PDF]
Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model
- Valder R. Arruda, Hansell H. Stedman, Timothy C. Nichols, Mark E. Haskins, Matthew Nicholson, Roland W. Herzog, Linda B. Couto, and Katherine A. High
Blood 2005; 105: 3458-3464.
[Abstract]
[Full text]
[PDF]
Ex vivo culture of Fancc-/- stem/progenitor cells predisposes cells to undergo apoptosis, and surviving stem/progenitor cells display cytogenetic abnormalities and an increased risk of malignancy
- Xiaxin Li, Michelle M. Le Beau, Samantha Ciccone, Feng-Chun Yang, Brian Freie, Shi Chen, Jin Yuan, Ping Hong, Attilio Orazi, Laura S. Haneline, and D. Wade Clapp
Blood 2005; 105: 3465-3471.
[Abstract]
[Full text]
[PDF]
Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy
- Lili Wang, Roberto Calcedo, Timothy C. Nichols, Dwight A. Bellinger, Aaron Dillow, Inder M. Verma, and James M. Wilson
Blood 2005; 105: 3079-3086.
[Abstract]
[Full text]
[PDF]
Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation
- Dinorah Friedmann-Morvinski, Alain Bendavid, Tova Waks, Daniel Schindler, and Zelig Eshhar
Blood 2005; 105: 3087-3093.
[Abstract]
[Full text]
[PDF]
|
|
